PEARL STUDY Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. 25th June 2022: Teva Pharmaceuticals Europe B.V. announced promising interim results from its Pan-European Real World study (PEARL),…
Breakthrough device for glioblastoma
Carthera receives FDA breakthrough device designation for SonoCloud-9 system, allowing for enhanced interaction with FDA and recognising SonoCloud system as innovative and promising approach for treatment of recurrent glioblastoma Carthera, a French company that designs and develops SonoCloud, an ultrasound-based medical device to treat a wide range of brain diseases, announced on June 22 2022 that…
Study: Improvements in TBI Patients with Persistent Brain Fog
A new study has shown that plasticity-based brain training can drive improvements in patients with persistent symptoms of Traumatic Brain Injury (TBI). Gains were observed in standard measures of cognition, standard measures of self-reported symptoms, and the connectivity between brain regions. The intervention used in the study was brain exercises from BrainHQ, made by Posit…
In Vitro diagnostic test for assessment of Alzheimer’s disease
The U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorisation for Fujirebio Diagnostics’ Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic (IVD) test for the assessment of β-Amyloid pathology in patients being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is…
Brain-computer interface helps paralysed patient drive again
Almost ten years ago, Aldana Zuniga was paralysed from the waist down in a car accident. Now, a microchip implanted in his brain has helped him get behind the wheel of a car again. Using only his thoughts to control the speed, Zuniga drove laps in a NASCAR Cup racecar on a track in the…
Management of urinary incontinence in adults with MS or SCI
Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to Multiple Sclerosis or Spinal Cord Injury Submission based on data from the pivotal international Phase III CONTENT clinical programme, also recently published in European Urology1 CONTENT showed that Dysport® decreased incontinence episodes, detrusor pressure and increased…
Chronic pain: discovery in the brains of army veterans could pave way for personalised treatments
Study is first to investigate the neural hallmarks of co-occurring chronic pain and trauma in veterans, finding high, medium, and low symptom groups Chronic pain and trauma often co-occur. However, most previous research investigated them in isolation and using subjective measures such as surveys, leading to an incomplete picture. A new study in Frontiers…
NICE Assessment for SPRAVATO®▼
Janssen was disappointed with the recent decision (27/5/22) by the National Institute for Health and Care Excellence (NICE) on their Final Appraisal Determination, in which SPRAVATO®▼ (esketamine) nasal spray has not been recommended for use within its marketing authorisation, in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI),…
Label Extension for Evrysdi®for Infants with SMA Under 2 Months Old
– Evrysdi is the first and only at-home administered treatment for patients living with SMA – Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date PTC Therapeutics, Inc. announced on May 31st 2022 that the US Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to…
